Funds will be used to advance Magenta’s US clinical programs to support the FDA’s approval of the Elevate™ System, the world’s smallest heart pump Eric Snyder, Partner, Venture Investments, Novo Holdings will join Magenta Medical Board of Directors Boston, US, 23 July 2024 – Novo Holdings, a leading life science investor, today announces that it has […]
Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]
• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]
Novo Holdings and A.P. Moller Holding have enabled a €150 million fundraise for CIRCTEC by leading with a €75 million equity investment. Financing includes €22.5 million of grants awarded by the Government of the Netherlands. The funding enables CIRCTEC to construct Europe’s largest end-of-life tyre pyrolysis recycling facility in Delfzijl, the Netherlands. The construction of […]
SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody Provides flexible loan facility to support additional clinical work and activities to drive its successful registration and commercialisation Funding is additional to recent $75m Series B financing Dublin, Ireland and Oxford, UK, 30 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), […]
